Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL

Journal of Lipid Research

Volumn 52, Issue 7, 2011, Pages 1363-1372

  Kateifides, Andreas K ^a,b   Gorshkova, Irina N ^a   Duka, Adelina ^a   Chroni, Angeliki ^c   Kardassis, Dimitris ^b   Zannis, Vassilis I ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CRETE   (Greece)

^c INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

Apolipoprotein A I mutations; Dyslipidemia; HDL biogenesis; Hypertriglyceridemia; LCAT; Lipoprotein lipase; Pre and HDL particles

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL ALPHA1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL ALPHA2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL ALPHA3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL ALPHA4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL BETA1; LIPID; LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADENOVIRUS; ANIMAL CELL; ARTICLE; BIOGENESIS; CELL SUBPOPULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DENATURATION; ENTHALPY; GENE TRANSFER; HOMEOSTASIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; HYPERTRIGLYCERIDEMIA; LIPID HOMEOSTASIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; THERMOSTABILITY;

ANILINO NAPHTHALENESULFONATES; ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL; CONSERVED SEQUENCE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; EMULSIONS; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; KINETICS; LIPOPROTEINS, HDL; MALE; MICE; MICE, INBRED C57BL; MUTAGENESIS; MUTATION; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; TEMPERATURE; TRIGLYCERIDES;

EID: 79959234286     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M012989     Document Type: Article

References (50)

1. Chroni, A., T. Liu, I. Gorshkova, H. Y. Kan, Y. Uehara, A. von Eckardstein, and V. I. Zannis. 2003. The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type apoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo. J. Biol. Chem. 278: 6719-6730.
2. Laccotripe, M., S. C. Makrides, A. Jonas, and V. I. Zannis. 1997. The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein. J. Biol. Chem. 272: 17511-17522.
3. Liu, T., M. Krieger, H. Y. Kan, and V. I. Zannis. 2002. The effects of mutations in helices 4 and 6 of apoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport. J. Biol. Chem. 277: 21576-21584.
4. Zannis, V. I., A. Chroni, K. E. Kypreos, H. Y. Kan, T. B. Cesar, E. E. Zanni, and D. Kardassis. 2004. Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Curr. Opin. Lipidol. 15: 151-166.
5. Kiss, R. S., N. Kavaslar, K. Okuhira, M. W. Freeman, S. Walter, R. W. Milne, R. McPherson, and Y. L. Marcel. 2007. Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arterioscler. Thromb. Vasc. Biol. 27: 1139-1145.
6. Cohen, J. C., R. S. Kiss, A. Pertsemlidis, Y. L. Marcel, R. McPherson, and H. H. Hobbs. 2004. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science. 305: 869-872.
7. Frikke-Schmidt, R., B. G. Nordestgaard, G. B. Jensen, and A. Tybjaerg-Hansen. 2004. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J. Clin. Invest. 114: 1343-1353.
8. Zannis, V. I., E. E. Zanni, A. Papapanagiotou, D. Kardassis, and A. Chroni. 2006. ApoA-I functions and synthesis of HDL: insights from mouse models of human HDL metabolism. In High-Density Lipoproteins. From Basic Biology to Clinical Aspects. Wiley-VCH, Weinheim. 237-265.
9. Koukos, G., A. Chroni, A. Duka, D. Kardassis, and V. I. Zannis. 2007. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT. Biochem. J. 406: 167-174.
10. Koukos, G., A. Chroni, A. Duka, D. Kardassis, and V. I. Zannis. 2007. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN. Biochemistry. 46: 10713-10721.
11. Chroni, A., A. Duka, H. Y. Kan, T. Liu, and V. I. Zannis. 2005. Point mutations in apolipoprotein a-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency. Biochemistry. 44: 14353-14366.
12. Chroni, A., H. Y. Kan, A. Shkodrani, T. Liu, and V. I. Zannis. 2005. Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice. Biochemistry. 44: 4108-4117.
13. Chroni, A., H. Y. Kan, K. E. Kypreos, I. N. Gorshkova, A. Shkodrani, and V. I. Zannis. 2004. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice. Biochemistry. 43: 10442-10457.
14. Wu, Z., V. Gogonea, X. Lee, R. P. May, V. Pipich, M. A. Wagner, A. Undurti, T. C. Tallant, C. Baleanu-Gogonea, F. Charlton, et al. 2011. The low resolution structure of ApoA1 in spherical high density lipoprotein revealed by small angle neutron scattering. J. Biol. Chem. 286: 12495-12508.
15. Silva, R. A., R. Huang, J. Morris, J. Fang, E. O. Gracheva, G. Ren, A. Kontush, W. G. Jerome, K. A. Rye, and W. S. Davidson. 2008. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc. Natl. Acad. Sci. USA. 105: 12176-12181.
16. Bashtovyy, D., M. K. Jones, G. M. Anantharamaiah, and J. P. Segrest. 2011. Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-function. J. Lipid Res. 52: 435-450.
17. Vezeridis, A. M., K. Drosatos, and V. I. Zannis. 2011. Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4. J. Lipid Res. 52: 45-56.
18. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
19. Fitzgerald, M. L., A. J. Mendez, K. J. Moore, L. P. Andersson, H. A. Panjeton, and M. W. Freeman. 2001. ATP-binding cassette transporter A1 contains an NH2-terminal signal anchor sequence that translocates the protein's first hydrophilic domain to the exoplasmic space. J. Biol. Chem. 276: 15137-15145.
20. Williamson, R., D. Lee, J. Hagaman, and N. Maeda. 1992. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 89: 7134-7138.
21. Zhu, L. J., and S. W. Altmann. 2005. mRNA and 18S-RNA coapplication-reverse transcription for quantitative gene expression analysis. Anal. Biochem. 345: 102-109.
22. Gorshkova, I. N., K. Liadaki, O. Gursky, D. Atkinson, and V. I. Zannis. 2000. Probing the lipid-free structure and stability of apolipoprotein A-I by mutation. Biochemistry. 39: 15910-15919.
23. Gorshkova, I. N., T. Liu, V. I. Zannis, and D. Atkinson. 2002. Lipidfree structure and stability of apolipoprotein A-I: probing the central region by mutation. Biochemistry. 41: 10529-10539.
24. Chen, Y. H., J. T. Yang, and H. M. Martinez. 1972. Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. Biochemistry. 11: 4120-4131.
25. Gorshkova, I. N., K. E. Kypreos, D. L. Gantz, V. I. Zannis, and D. Atkinson. 2008. Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia. Biochemistry. 47: 12644-12654.
26. Derksen, A., and D. M. Small. 1989. Interaction of ApoA-1 and ApoE-3 with triglyceride-phospholipid emulsions containing increasing cholesterol concentrations. Model of triglyceride-rich nascent and remnant lipoproteins. Biochemistry. 28: 900-906.
27. Gorshkova, I. N., and D. Atkinson. 2011. Enhanced binding of apolipoprotein A-I variants associated with hypertriglyceridemia to triglyceride-rich particles. Biochemistry. 50: 2040-2047.
28. Gorshkova, I. N., T. Liu, H. Y. Kan, A. Chroni, V. I. Zannis, and D. Atkinson. 2006. Structure and stability of apolipoprotein A-I in solution and in discoidal high-density lipoprotein probed by double charge ablation and deletion mutation. Biochemistry. 45: 1242-1254.
29. Segrest, J. P., M. K. Jones, A. E. Klon, C. J. Sheldahl, M. Hellinger, H. De Loof, and S. C. Harvey. 1999. A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J. Biol. Chem. 274: 31755-31758.
30. Jones, M. K., A. Catte, J. C. Patterson, F. F. Gu, J. G. Chen, L. Li, and J. P. Segrest. 2009. Thermal stability of apolipoprotein A-I in high-density lipoproteins by molecular dynamics. Biophys. J. 96: 354-371.
31. Gogonea, V., Z. P. Wu, X. Lee, V. Pipich, X. M. Li, A. I. Ioffe, J. A. Didonato, and S. L. Hazen. 2010. Congruency between Biophysical Data from Multiple Platforms and Molecular Dynamics Simulation of the Double-Super Helix Model of Nascent High-Density Lipoprotein. Biochemistry. 49: 7323-7343.
32. Timmins, J. M., J. Y. Lee, E. Boudyguina, K. D. Kluckman, L. R. Brunham, A. Mulya, A. K. Gebre, J. M. Coutinho, P. L. Colvin, T. L. Smith, et al. 2005. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 115: 1333-1342.
33. Miettinen, H. E., H. Gylling, T. A. Miettinen, J. Viikari, L. Paulin, and K. Kontula. 1997. Apolipoprotein A-IFin. Dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene. Arterioscler. Thromb. Vasc. Biol. 17: 83-90.
34. Xiao, C., T. Watanabe, Y. Zhang, B. Trigatti, L. Szeto, P. W. Connelly, S. Marcovina, T. Vaisar, J. W. Heinecke, and G. F. Lewis. 2008. Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Circ. Res. 103: 159-166.
35. Teslovich, T. M., K. Musunuru, A. V. Smith, A. C. Edmondson, I. M. Stylianou, M. Koseki, J. P. Pirruccello, S. Ripatti, D. I. Chasman, C. J. Willer, et al. 2010. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 466: 707-713.
36. Brunzell, J. D. ( 1989 ) Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 1165-1180.
37. Baggio, G., E. Manzato, C. Gabelli, R. Fellin, S. Martini, G. B. Enzi, F. Verlato, M. R. Baiocchi, D. L. Sprecher, and M. L. Kashyap. 1986. Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. J. Clin. Invest. 77: 520-527.
38. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1990. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 249: 790-793.
39. de Silva, H. V., S. J. Lauer, J. Wang, W. S. Simonet, K. H. Weisgraber, R. W. Mahley, and J. M. Taylor. 1994. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J. Biol. Chem. 269: 2324-2335.
40. Shachter, N. S., T. Hayek, T. Leff, J. D. Smith, D. W. Rosenberg, A. Walsh, R. Ramakrishnan, I. J. Goldberg, H. N. Ginsberg, and J. L. Breslow. 1994. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J. Clin. Invest. 93: 1683-1690.
41. Boisfer, E., G. Lambert, V. Atger, N. Q. Tran, D. Pastier, C. Benetollo, J. F. Trottier, I. Beaucamps, M. Antonucci, M. Laplaud, et al. 1999. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J. Biol. Chem. 274: 11564-11572.
42. Kypreos, K. E., K. W. Van Dijk, A. van Der Zee, L. M. Havekes, and V. I. Zannis. 2001. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. J. Biol. Chem. 276: 19778-19786.
43. Kypreos, K. E., X. Li, K. W. Van Dijk, L. M. Havekes, and V. I. Zannis. 2003. Molecular mechanisms of type III hyperlipoproteinemia: the contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype. Biochemistry. 42: 9841-9853.
44. Pennacchio, L. A., M. Olivier, J. A. Hubacek, J. C. Cohen, D. R. Cox, J. C. Fruchart, R. M. Krauss, and E. M. Rubin. 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 294: 169-173.
45. Chait, A., W. R. Hazzard, J. J. Albers, R. P. Kushwaha, and J. D. Brunzell. 1978. Impaired very low density lipoprotein and triglyceride removal in broad beta disease: comparison with endogenous hypertriglyceridemia. Metabolism. 27: 1055-1066.
46. Fredenrich, A. 1998. Role of apolipoprotein CIII in triglyceriderich lipoprotein metabolism. Diabetes Metab. 24: 490-495. (Pubitemid 29048417)
47. Fredrickson, D. S., P. H. Altrocchi, L. V. Avioli, D. S. Goodman, and H. C. Goodman. 1961. Tangier disease. Combined clinical staff conference at the National Institutes of Health. Ann. Intern. Med. 55: 1016-1031.
48. Heinen, R. J., P. N. Herbert, and D. S. Fredrickson. 1978. Properties of the plasma very low and low density lipoproteins in Tangier disease. J. Clin. Invest. 61: 120-132.
49. Chiesa, G., L. J. Stoltzfus, S. Michelagnoli, J. K. Bielicki, M. Santi, T. M. Forte, C. R. Sirtori, G. Franceschini, and E. M. Rubin. 1998. Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-I(Milano). Atherosclerosis. 136: 139-146.
50. Nofer, J. R., A. von Eckardstein, H. Wiebusch, W. Weng, H. Funke, H. Schulte, E. Kohler, and G. Assmann. 1995. Screening for naturally occurring apolipoprotein A-I variants: apo A-I(delta K107) is associated with low HDL-cholesterol levels in men but not in women. Hum. Genet. 96: 177-182.